23andMe’s face in the crowdsourced health research industry gets bigger

The burgeoning field of do-it-yourself biomedical research got a major endorsement this week when the genetic testing heavyweight 23andMe announced it had bought the community health site CureTogether for an undisclosed sum.

With CureTogether, a social networking site that enables users to conduct their own research studies by sharing and aggregating health information, California-based 23andMe appears to be getting serious about expanding its efforts in the Web-based, participant-driven research arena.

Already, peer-reviewed studies involving 23andMe’s 150,000 customers have yielded novel genetic insights into Parkinson’s diseasehypothyroidism and common traits such as freckling. CureTogether’s infrastructure and user base—which span some 500 medical conditions—should only make such patient-driven research easier.

“There are tremendous opportunities for our members and for future research by integrating the 23andMe and the CureTogether platforms and phenotypic data,” CureTogether cofounder Daniel Reda, who will now serve as 23andMe’s senior product manager, said in a statement.

23andMe will face competition, though. PatientsLikeMeQuantified Self and DIYgenomics are just a few of the community portals that now facilitate crowdsourced biomedical research. “Participatory health initiatives are becoming part of the public health ecosystem,” Melanie Swan, the founder of DIYgenomics, wrote in a study published earlier this year the Journal of Medical Internet Research.

Two years ago, Nature Medicine profiled one such participatory health startup called Genomera (see ‘Personalized investigation’ from our September 2010 issue). At the time, chief executive Greg Biggers was just developing the Palo Alto, California-based company’s platforms. But in the intervening years, Biggers has been busy tweaking the cloud-based software, testifying before the Presidential Commission for the Study of Bioethical Issues about amateurs participating in research and helping academics, as well as lay users, run analyses on his website.

Now, Biggers says his goal of a prospective, longitudinal study that can yield scientifically valid results has almost been achieved. Currently, the site hosts an ongoing study that is examining the effects of whole-fat butter on human cognition. (Biggers declined to share more details from the study on his beta site.)

“Since the first study we helped orchestrate [on vitamin B metabolism], we have proven two important items,” he says. “That participant-driven research is credible and productive, and that Internet study operations bring efficiency and scale to the world of health research.”

That’s a message that still has some skeptics in the ivory towers of most universities, but it doesn’t seem to have escaped 23andMe.

Photo courtesy of  Bruce Rolff via Shutterstock

Genentech, 23andMe to study genetic response to breast cancer drug

Personal-genomics company 23andMe, based in Mountain View, California, and biotechnology firm Genentech, based in San Francisco, are recruiting patients with breast cancer to study genetic predictors of how well they respond to the drug Avastin (bevacizumab).

Genentech’s Avastin is approved to treat several cancers, but in November, the US Food and Drug Administration (FDA) revoked approval to use the drug in certain breast cancers that have metastasized, or spread beyond the initial site of the tumour. The decision came in light of studies done after the drug’s 2008 approval for breast cancer that found, the FDA said, “only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone — not enough to outweigh the risk of taking the drug.”

Genentech said at the time that it would look for potential biomarkers that could identify the groups of patients with breast cancer who would be most likely to benefit from taking the drug.

23andMe has been turning increasingly towards research studies as consumer demand for its services has plateaued.

23andMe is seeking DNA donations from individuals with metastatic breast cancer who have taken Avastin; in return, it will grant them access to its genome-profiling service. Patient groups are supporting the study.